# **ORIGINAL ARTICLE**

# Impact of geriatric assessment variables on 30-day mortality among older patients with acute heart failure

Francisco Javier Martín-Sánchez<sup>1,2</sup>, Esther Rodríguez-Adrada<sup>2</sup>, María Teresa Vidán<sup>3</sup>, Pablo Díez Villanueva<sup>4</sup>, Guillermo Llopis García<sup>1</sup>, Juan González del Castillo<sup>1,2</sup>, Miguel Alberto Rizzi<sup>5</sup>, Aitor Alquézar<sup>5</sup>, Sergio Herrera Mateo<sup>5</sup>, Pascual Piñera<sup>6</sup>, José Andrés Sánchez Nicolás<sup>6</sup>, Paula Lázaro Aragues<sup>6</sup>, Pere Llorens<sup>7</sup>, Pablo Herrero<sup>8</sup>, Javier Jacob<sup>9</sup>, Víctor Gil<sup>10</sup>, Cristina Fernández<sup>2,11</sup>, Héctor Bueno<sup>12</sup>, Òscar Miró<sup>10</sup>

**Objective.** To study the impact of geriatric assessment variables on 30-day mortality among older patients with acute heart failure (AHF).

**Methods.** Retrospective analysis of cases in the OAK Registry (Older Acute Heart Failure Key Data), a prospectively compiled database of consecutive patients aged 65 years or older treated for AHF in 3 Spanish emergency departments over a 4-month period (November-December 2011 and January-February 2014). The patients underwent a geriatric assessment adapted for emergency department use on weekdays between 8 AM and 10 PM. Demographic, clinical, laboratory, and geriatric assessment variables were recorded. The geriatric variables were concurrent diseases; polypharmacy; frailty; functional, social, and cognitive status at baseline; results of screening for confusional state, cognitive impairment, and depression; and nutritional status. The primary outcome was all-cause mortality at 30 days.

**Results.** We included 565 patients with a mean (SD) age of 83 (7.1) years; 346 (61.6%) were women. Sixty-five (11.5%) died within 30 days. Independent factors associated with 30-day mortality were acute confusional state (adjusted odds ratio [aOR], 2.2; 95% Cl, 1.0–4.8; P=.04), acute illness (aOR, 1.8; 95% Cl, 0.9–3.4; P=.05), loss of appetite in the past 3 months (aOR, 1.8; 95% Cl, 1.0–3.4; P=.04), frailty (aOR, 2.0, 95% Cl, 1.0–4.1; P=.05), and severe disability (aOR, 4.4; 95% Cl, 1.9–11.4; P=.01).

**Conclusions.** Certain geriatric variables should be considered when assessing short-term risk in older patients with AHF.

Keywords: Frailty. Disability. Confusional state. Acute heart failure.

# Impacto de las variables geriátricas en la mortalidad a 30 días de los ancianos atendidos por insuficiencia cardiaca aguda

**Objetivos.** Estudiar el impacto de las variables geriátricas en la mortalidad a 30 días entre los ancianos con insuficiencia cardiaca aguda (ICA).

**Método.** Análisis retrospectivo del registro Older Acute heart failure Key data (OAK) que incluye prospectivamente a pacientes consecutivos  $\geq$  65 años con ICA en 3 servicios de urgencias españoles durante 4 meses (noviembre-diciembre 2011 y enero-febrero 2014). Se realizó una valoración geriátrica adaptada a urgencias durante los días laborales de 8 am a 10 pm. Se recogieron variables demográficas, clínicas, analíticas y geriátricas (comorbilidad, polifarmacia, fragilidad, situación basal funcional, cognitiva y social, despistaje de síndrome confusional, deterioro cognitivo y depresión, y situación nutricional). La variable de resultado fue la mortalidad por cualquier causa a los 30 días.

**Resultados.** Se incluyeron 565 pacientes con edad media 83 años (DE 7,1), 346 mujeres (61,6%). Sesenta y cinco sujetos (11,5%) fallecieron a los 30 días. La presencia de síndrome confusional agudo (OR ajustada = 2,2; IC95% 1,0-4,8; p = 0,04), de enfermedad aguda (OR ajustada = 1,8; IC95% 0,9-3,4; p = 0,05) o pérdida de apetito (OR ajustada = 1,8; IC95% 1-3,4; p = 0,04) en los últimos 3 meses, y de fragilidad (OR ajustada = 2,0; IC95% 1,0-4,1; p = 0,05) o dependencia funcional grave (OR ajustada = 4,4; IC95% 1,9-11,4; p = 0,01) fueron factores independentes asociados con mortalidad a los 30 días.

**Conclusiones.** Existen ciertas variables geriátricas que debieran contemplarse en la estratificación de riesgo a corto plazo de los pacientes ancianos con ICA.

Palabras clave: Fragilidad. Discapacidad. Síndrome confusional. Insuficiencia cardiaca aguda.

#### Authors affiliation:

<sup>1</sup>Emergency Service, San Carlos Clinical Hospital, Madrid, Spain. <sup>2</sup>Instituto de Investigacion Sanitaria Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, Spain. <sup>3</sup>Geriatrics Service, Gregorio Marañón Hospital, liSGM Research Institute, Complutense University of Madrid, Spain. <sup>4</sup>Cardiology Service, La Princesa University Hospital, Madrid, Spain. Émergency Service, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain. Emergency Service, Reina Sofia Hospital, Murcia, Spain. <sup>7</sup>Emergency Service, General Hospital of Alicante: Institute of Health and Biomedical Research of Alicante (ISABIAI FISABIO Foundation). University Miguel Hernández from Alicante Spain. <sup>8</sup>Émergency Service, Central Hospital of Asturias, Oviedo, Spain. Emergency Service, Hospital Universitari de Bellvitge L'Hospitalet de Llobregat. Barcelona, Spain. <sup>10</sup>Emergency Area, Hospital Clínic, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. <sup>11</sup>Service of Preventive Medicine, San Carlos Clinical Hospital, Madrid, Spain. <sup>12</sup>National Centre for Cardiovascular Research (CNIC), Madrid; Research Institute i+12, Cardiology Service, University Hospital 12 de Octubre, Madrid; Universidad Complutense de Madrid, Spain.

Contribution of authors: All authors have confirmed their authorship in the author's responsibilities documents publication agreement and assignment of rights to EMERGENCIAS.

Corresponding author: F. Javier Martín-Sánchez Servicio de Urgencias Hospital Clínico San Carlos Calle Profesor Martín-Lagos, s/n 28040 Madrid, Spain

E-mail: fjjms@hotmail.com

**Article information:** Received: 18-03-2017 Accepted: 18-04-2017 Online: 25-7-2017

Editor in charge: Agustín Julián-Jiménez, MD, PhD.

# Introduction

Acute heart failure (AHF) is one of the main causes of care in emergency medical systems and in hospital emergency services (HES) in the elderly population and is associated with poor short-term outcomes<sup>1-3</sup>. The role of the emergency physician is to carry out the initial management of the process, the decision of admission and the design of a care<sup>4-6</sup>. Risk models have been derived in order to help in this decision-making process, which include various scales for risk stratification in AHF that allow predicting the short-term prognosis of patients<sup>7-10</sup>. A recent study concluded that risk models have shown a very limited predictive capacity in the elderly population<sup>11</sup>.

It has been described that comorbidity, polypharmacy, cognitive, functional, social and nutritional status and the presence of frailty and geriatric syndromes are independent factors of poor prognosis among elderly patients hospitalized by AHF<sup>12-18</sup>. At present, there is no known work developed to analyze the effect on short-term prognosis of different variables, such as comorbidity, polypharmacy, frailty, cognitive, functional, social and nutritional, and the presence of geriatric syndromes, specifically in the elderly population with AHF treated in the HES. Therefore, the main objective of the study was to know the impact of the different geriatric variables on prognosis at 30 days among elderly patients treated for AHF in HES.

# Method

This is a retrospective analysis of the Older Acute Heart Failure Key Data (OAK) Registry, an observational multicentre and multi-centre cohort study<sup>19</sup>. The study was approved by the Research Ethics Committees (REC) of the participating centres.

The OAK registry prospectively included all patients  $\geq$  65 years attended by AHF in 3 Spanish HES (Hospital Clínico San Carlos -HCSC-, Madrid, Hospital Reina Sofía -HRS, Murcia, and Hospital Santa Creu i Sant Pau -HSCSP-, Barcelona), during 4 months, in periods of 2 months (November-December 2011 and January February 2014), who gave their consent to participate in the study. All patients diagnosed with AHF were initially selected by the physician responsible for emergencies based on clinical, electrocardiographic and radiological findings, and if available, with data on plasma concentrations of B-type natriuretic peptides and ultrasound. The chief investigator of each centre reviewed all the cases and finally included only those who met the diagnostic criteria of the heart failure guidelines of the European Society of Cardiology in force at the time of the study<sup>20</sup>. We excluded patients with acute myocardial infarction with segment elevation to ST as precipitating factor of AHF.

For the present study, patients from the OAK registry were selected in which a geriatric assessment adapted to the emergency department was performed at the time of first care and in which follow-up data were available 30 days after the index visit.

The physicians responsible for emergency care collected the demographic data (age and gender), personal history (hypertension, diabetes mellitus -DM-, ischemic heart disease, valvular heart disease, atrial fibrillation, cerebrovascular disease, chronic renal failure, peripheral arterial disease, disease chronic obstructive pulmonary disease -COPD-, cirrhosis, cancer, previous episode of heart failure and left ventricle function), baseline cardiorespiratory status (according to the New York Heart Association class -NYHA-), clinical and analytical data of the acute episode (systolic blood pressure (SBP), heart and respiratory rate, baseline oxygen saturation by pulse oximetry, hemoglobin, natremia, renal clearance calculated by MDRD-4 and natriuretic peptide type B -NT-proBNP-) and the treatment directed during their stay in the emergency department (oxygen, non-invasive mechanical ventilation, intravenous diuretics, intravenous nitroglycerin, angiotensin-converting enzyme inhibitors -IACE inhibitors-, aldosterone receptor antagonists -RA-, beta-blockers and digoxin).

A medical researcher from each center performed a geriatric assessment adapted to the emergency department during the working days from 8 am to 10 pm. The adapted geriatric assessment included the personal history of diagnosis of dementia or depression, the degree of comorbidity (severe if  $\geq$  3 points according to the Charlson index), the number of drugs taken chronically (polypharmacy if  $\geq 5$  medications), the situation functional basal (Barthel index), the fragility screening (fragility if  $\geq$  3 Fried modified fragility criteria: 1) fatigue: do you often feel that everything you do is an effort?; 2) muscle strength: do you have difficulty getting up from a chair? 3) slowness of walking: do you have significant difficulty walking outside your home?; 4) physical activity: do you practice physical activity on a regular basis? and 5) weight loss: have you lost weight unintentionally in the last year?) in those without serious functional dependence (Barthel index  $\geq$  40 points), the short confusional syndrome (confusional picture if presented a positive Confussion Assessment Method -CAM-), the screening for dementia (probable dementia if  $\geq 3$ points of the Six-Item Screener -SIS-) and depression (probable depression if  $\geq 2$  points Geriatric Depression Scale of 5 questions -GDS-5-) in those without the presence of confusional symptoms, the answer to two questions collected in the Mini MNA related to the self-perception of the health and nutritional status (have you lost appetite or have eaten less due to lack of appetite, digestive problems, masticatory difficulties or swallowing? the last 3 months? and have you had an illness acute or psychological stress situation in the last 3 months?), the self-reported presence of deficit of visual or auditory acuity and living alone.

The main outcome variable was mortality by any cause 30 days after the index event by reviewing the clinical history or telephone call to each patient or companion between 31 and 60 days after the HES care.

For statistical analysis, quantitative variables were expressed as means and standard deviation (SD) and gualitative variables as absolute numbers and percentages. For the univariable analysis of the quantitative variables, the Student test was used, after checking with the Kolmogorov-Smirnov test that they fit a normal distribution, and for the qualitative test the chi-square test or Fisher's exact test correspond A logistic regression analysis was carried out that included all the cardiological variables with a value of p < 0.10 in the univariate analysis or with clinical relevance described in the literature11 and, subsequently, the geriatric variables previously identified as independently associated with the mortality at 30 days. The effects of the geriatric variables on 30-day mortality were determined, expressed as crude odds ratio (OR) (with its corresponding 95% confidence interval, -IC 95%-), and subsequently adjusted, first by the non-cardiological variables and, subsequently, both by the cardiological and non-cardiological variables. The differences were considered as statistically significant if the p value was < 0.05, the 95% CI of the OR excluded the value 1. The statistical analysis was performed with the SPSS version 18.0 for Windows (SPSS Inc., Chicago, EE .UU).

### Results

We selected 565 patients from the 952 cases of the OAK registry for the present study. We excluded 349 patients in whom the geriatric assessment had not been performed and 38 patients due to lack of data on follow-up at 30 days. The comparison between included and non-included patients found no statistically significant differences except for age, history of DM and COPD, baseline cardiorespiratory status and the presence of respiratory failure on arrival at the emergency room (Table 1).

The patients included in the study had a mean age 83 (SD 7.1) years, 346 (61.6%) were women and 357 (63.2%) had had a previous episode of AHF. Sixty-five (11.5%) subjects died within 30 days of emergency care. Table 2 shows the characteristics of patients globally and grouped according to 30-day mortality.

Table 3 reflects the frequency of appearance of the geriatric variables in the elderly population with AHF. The history of dementia (p < 0.01) or depression (p = 0.02), the presence of acute confusional syndrome in the emergency department (p < 0.01), the existence of frailty or severe disability (p < 0.01) ), having suffered a disease recent acute (p < 0.01) or loss of appetite in the last 3 months (p < 0.01) and the visual acuity deficit (p = 0.03) were asso-

Table 1. Characteristics	of patients included	l and not included
in the study		

	Included patients (N = 565) n (%)	Non- included patients (N = 387) n (%)	р
Demographic data			
Age (years) [mean (SD)] Sex female	83.4 (7.1) 346 (61.6)	82.6 (7.0) 235 (60.6)	0.01 0.77
Personal history			
Arterial hypertension Diabetes mellitus Ischemic heart disease Chronic renal failure Cerebrovascular disease Atrial fibrillation Peripheral vascular disease Valvulopathy Chronic obstructive pulmonary	497 (88.0) 201 (35.6) 167 (29.6) 171 (30.3) 94 (16.6) 263 (47.1) 85 (15.0) 172 (30.4)	332 (85.6) 169 (43.6) 98 (25.3) 101 (26.0) 63 (16.2) 159 (41.5) 47 (12.1) 109 (28.1)	0.28 0.01 0.13 0.15 0.80 0.09 0.20 0.45
Dravious apisodo of boart	120 (22.3)	109 (28.1)	0.05
failure Cirrhosis	357 (63.2) 17 (3.0)	238 (64.2) 10 (2.6) 59 (15.2)	0.82
Basal situation	95 (10.5)	59 (15.2)	0.05
Cardiorespiratory status (NYHA III-IV) IVEF < 45%	137 (24.6) 101 (57 7)	68 (18.2) 65 (59 1)	0.02
Acute episode data	101 (07.77)	00 (07.17)	0.70
Hypotension (SBP < 100 mmHg) Tachycardia (HR ≥ 100 bpm) Tachypnea (RR > 20 rpm) Respiratory insufficiency	28 (5.0) 137 (24.6) 222 (39.3)	15 (3.9) 104 (27.1) 137 (47.1)	0.46 0.39 0.25
(Basal $O_2$ Sat < 90%) Hyponatremia (Na < 135 mEg/L)	146 (27.4) 89 (16.0)	80 (21.4) 70 (18.3)	0.04 0.37
Renal insufficiency (Cl < 60 ml/min/m <sup>2</sup> ) Anemia (Hb < 12 g/L woman and	323 (59.0)	244 (63.9)	0.07
<13 g/l male) NT-proBNP > 5,180 pg/ml	305 (54.9) 339 (60.0)	200 (52.2) 218 (56.3)	0.44 0.28
Follow up			
30 day mortality	65 (11.5)	35 (10.0)	0.23

SD: Standard deviation; n: number of cases, NYHA New York Heart Association; SBP: Systolic blood pressure; HR: Heart rate; RR: Respiratory rate; bpm: Beats per minute; rpm: Respirations per minute; O<sub>2</sub>Sat: oxygen saturation; Na: Natremia; Cl: Estimated Renal clearance; LVEF: ejection fraction of the left ventricle; Hb: hemoglobin.

cia≥ted in a statistically significant way with the poor prognosis at 30 days.

Figure 1 shows the raw and adjusted effects of each of these variables. After the multivariate analysis, the presence of acute confusional syndrome (adjusted OR = 2.2, 95% Cl 1.0-4.8, p = 0.04), of acute disease (adjusted OR = 1.8, 95% Cl 0, 9-3.4, p = 0.05) or loss of appetite (adjusted OR = 1.8, 95% Cl 1-3.4, p = 0.04) in the last 3 months, and frailty (OR adjusted = 2.0, 95% Cl 1.0-4.1, p = 0.05) or severe functional dependence (adjusted OR = 4.4, 95% Cl 1.9-11.4, p = 0.01) independent factors associated with 30-day mortality were possible.

# Discussion

The present study shows that the geriatric variables are frequent in the elderly with AHF seen in the

Demographic data           Age (years) [mean (SD)] $83.4$ (7.1) $86.4$ (6.7) $83.0$ (7.0)         < 0.01           Sex female $346$ (61.6) $38$ (58.5) $308$ (62.0)         0.58           Personal history           Adv (61.6) $38$ (58.5) $308$ (62.0)         0.58           Personal history           440 (88.0)         0.94           Diabetes mellitus         201 (35.6)         18 (27.7)         183 (36.6)         0.15           Ischemic heart disease         167 (29.6)         19 (29.2)         148 (29.6)         0.34           Cerebrowascular disease         94 (16.6)         14 (21.5)         80 (16.0)         0.25           Atrial fibrillation         263 (47.1)         26 (40.6)         237 (48.0)         0.26           Peripheral vascular disease         85 (15.0)         8 (12.3)         77 (15.4)         0.51           Valvulopathy         172 (30.4)         17 (26.2)         155 (31.0)         0.42           Chronic obstructive pulmonary disease         126 (22.3)         15 (23.1)         111 (22.1)         0.87           Previous episode of heart failure         357 (63.2)         41 (63.1)         316 (63.2)         0.98		Total (N = 565) n (%)	Dead 30 days after (N = 65) n (%)	Alive 30 days after (N = 500) n (%)	Р
Age (vears) [mean (SD)] $83.4$ (7.1) $86.4$ (6.7) $83.0$ (7.0)< 0.01Sex female $346$ (61.6) $38$ (S5.5) $308$ (62.0) $0.58$ Personal history	Demographic data				
Sex female 346 (61.6) 38 (58.5) 308 (62.0) 0.58 Personal history $\begin{tabular}{ c c c c } \hline Personal history & 201 (35.6) 18 (27.7) 440 (88.0) 0.94 Diabetes mellitus 201 (35.6) 18 (27.7) 183 (36.6) 0.15 Ischemic heart disease 167 (29.6) 19 (29.2) 148 (29.6) 0.95 Chronic renal failure 171 (30.3) 23 (35.4) 148 (29.6) 0.34 Cerebrovascular disease 94 (16.6) 14 (21.5) 80 (16.0) 0.25 Atrial fibrillation 263 (47.1) 26 (40.6) 237 (48.0) 0.26 Peripheral vascular disease 85 (15.0) 8 (12.3) 77 (15.4) 0.51 Valvulopathy 172 (30.4) 17 (26.2) 155 (31.0) 0.42 Chronic obstructive pulmonary disease 126 (22.3) 15 (23.1) 111 (22.1) 0.87 Previous episode of heart failure 357 (63.2) 41 (63.1) 316 (63.2) 0.98 Cirrhosis 17 (3.0) 4 (6.2) 13 (2.6) 0.11 Cancer 93 (16.5) 15 (23.1) 78 (15.6) 0.12 Basal situation Cardiorespiratory status (NYHA III-IV) 137 (24.6) 22 (34.9) 115 (23.2) 0.04 LVEFI ≤ 45% (n= 175) 101 (57.7) 3 (21.4) 71 (44.1) 0.10 Acute episode dat Hypotension (SBP < 100 mmHg) 137 (24.6) 12 (18.5) 125 (25.4) 0.22 Tachypardia (HR ≥ 100 bpm) 137 (24.6) 12 (18.5) 125 (25.4) 0.22 Tachypardia (HR ≥ 100 bpm) 137 (24.6) 12 (18.5) 125 (25.4) 0.22 Tachypardia (HR ≥ 100 bpm) 137 (24.6) 12 (18.5) 117 (24.9) 0.01 Hyponatremia (Na < 135 mEq/L) 89 (16.0) 18 (29.5) 71 (14.4) 0.01 Respiratory insufficiency (6asal 02Sat < 90%) 146 (27.4) 29 (45.3) 117 (24.9) 0.01 Hyponatremia (Na < 135 mEq/L) 89 (16.0) 18 (29.5) 71 (14.4) 0.01 Renal insufficiency (< 60 ml/min/m2) 323 (59.0) 34 (56.7) 289 (59.3) 0.69 Anemia (Hb < 12 g/L woman andCl < 13 g/l male) 305 (54.9) 45 (71.4) 260 (52.7) 0.01 NT-proBNP > 5,180 0g/ml 339 (60.0) 52 (80.0) 287 (57.4) < 0.01 Preatment of the acute episode$	Age (years) [mean (SD)]	83.4 (7.1)	86.4 (6.7)	83.0 (7.0)	< 0.01
Personal history         Arterial hypertension       497 (88.0)       57 (87.7)       440 (88.0)       0.94         Diabetes mellitus       201 (35.6)       18 (27.7)       183 (36.6)       0.15         Ischemic heart disease       167 (29.6)       19 (29.2)       148 (29.6)       0.34         Cerebrovascular disease       94 (16.6)       14 (21.5)       80 (16.0)       0.25         Atrial fibrillation       263 (47.1)       26 (40.6)       237 (48.0)       0.26         Peripheral vascular disease       85 (15.0)       8 (12.3)       77 (15.4)       0.51         Valvulopathy       172 (30.4)       17 (26.2)       155 (31.0)       0.42         Chronic obstructive pulmonary disease       126 (22.3)       15 (23.1)       111 (22.1)       0.87         Previous episode of heart failure       357 (63.2)       41 (63.1)       316 (63.2)       0.98         Cirrhosis       17 (3.0)       4 (6.2)       13 (2.6)       0.11         Cancer       93 (16.5)       15 (23.1)       71 (44.1)       0.10         Basal situation       137 (24.6)       22 (34.9)       115 (23.2)       0.04         LVET ≤ 45% (n= 175)       137 (24.6)       12 (18.5)       125 (25.4)       0.22 <t< td=""><td>Sex female</td><td>346 (61.6)</td><td>38 (58.5)</td><td>308 (62.0)</td><td>0.58</td></t<>	Sex female	346 (61.6)	38 (58.5)	308 (62.0)	0.58
Arterial hypertension497 (88.0)57 (87.7)440 (88.0)0.94Diabetes mellitus201 (35.6)18 (27.7)183 (36.6)0.15Ischemic heart disease167 (29.6)19 (29.2)148 (29.6)0.95Chronic renal failure171 (30.3)23 (35.4)148 (29.6)0.34Cerebrovascular disease94 (16.6)14 (21.5)80 (16.0)0.25Atrial fibrillation263 (47.1)26 (40.6)237 (48.0)0.26Peripheral vascular disease85 (15.0)8 (12.3)77 (15.4)0.51Valvulopathy172 (30.4)17 (26.2)155 (31.0)0.42Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVET I ≤ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode data	Personal history				
Diabetes mellitus201 (35.6)18 (27.7)183 (36.6)0.15Ischemic heart disease167 (29.6)19 (29.2)148 (29.6)0.95Chronic renal failure171 (30.3)23 (35.4)148 (29.6)0.34Cerebrovascular disease94 (16.6)14 (21.5)80 (16.0)0.25Atrial fibrillation263 (47.1)26 (40.6)237 (48.0)0.26Peripheral vascular disease85 (15.0)8 (12.3)77 (15.4)0.51Valvulopathy172 (30.4)17 (26.2)155 (31.0)0.42Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)71 (44.1)0.10Acute episode dataT137 (24.6)22 (34.9)115 (23.2)0.04LVEFI ≤ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataT137 (24.6)12 (18.5)125 (25.4)0.22Tachypnea (RR > 20 rpm)222 (39.3)35 (53.8)187 (37.4)0.01Respiratory insufficiency (Basal O <sub>2</sub> Sat < 90%)	Arterial hypertension	497 (88.0)	57 (87.7)	440 (88.0)	0.94
Ischemic heart disease167 (29.6)19 (29.2)148 (29.6)0.95Chronic renal failure171 (30.3)23 (35.4)148 (29.6)0.34Cerebrovascular disease94 (16.6)14 (21.5)80 (16.0)0.25Atrial fibrillation263 (47.1)26 (40.6)237 (48.0)0.26Peripheral vascular disease85 (15.0)8 (12.3)77 (15.4)0.51Valvulopathy172 (30.4)17 (26.2)155 (31.0)0.42Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirnchosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationT137 (24.6)22 (34.9)115 (23.2)0.04LVEFI ≤ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Actute episode dataT137 (24.6)12 (18.5)125 (25.4)0.22Hypotension (SBP < 100 mmHg)	Diabetes mellitus	201 (35.6)	18 (27.7)	183 (36.6)	0.15
Chronic renal failure       171 (30.3)       23 (35.4)       148 (29.6)       0.34         Cerebrovascular disease       94 (16.6)       14 (21.5)       80 (16.0)       0.25         Atrial fibrillation       263 (47.1)       26 (40.6)       237 (48.0)       0.26         Peripheral vascular disease       85 (15.0)       8 (12.3)       77 (15.4)       0.51         Valvulopathy       172 (30.4)       17 (26.2)       155 (31.0)       0.42         Chronic obstructive pulmonary disease       126 (22.3)       15 (23.1)       111 (22.1)       0.87         Previous episode of heart failure       357 (63.2)       41 (63.1)       316 (63.2)       0.98         Cirrhosis       17 (3.0)       4 (6.2)       13 (2.6)       0.11         Cancer       93 (16.5)       15 (23.1)       78 (15.6)       0.12         Basal situation       T       37 (24.6)       22 (34.9)       115 (23.2)       0.04         LVEFI ≤ 45% (n= 175)       101 (57.7)       3 (21.4)       71 (44.1)       0.10         Acute episode data       T       137 (24.6)       12 (18.5)       125 (25.4)       0.22         Tachypnea (RR > 20 rpm)       137 (24.6)       12 (18.5)       125 (25.4)       0.22         Tachypnea (RR >	Ischemic heart disease	167 (29.6)	19 (29.2)	148 (29.6)	0.95
Cerebrovascular disease94 (16.6)14 (21.5)80 (16.0)0.25Atrial fibrillation263 (47.1)26 (40.6)237 (48.0)0.26Peripheral vascular disease85 (15.0)8 (12.3)77 (15.4)0.51Valvulopathy172 (30.4)17 (26.2)155 (31.0)0.42Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI ≤ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataHypotension (SBP < 100 mmHg)	Chronic renal failure	171 (30.3)	23 (35.4)	148 (29.6)	0.34
Atrial fibrillation263 (47.1)26 (40.6)237 (48.0)0.26Peripheral vascular disease85 (15.0)8 (12.3)77 (15.4)0.51Valvulopathy172 (30.4)17 (26.2)155 (31.0)0.42Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI ≤ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataHypotension (SBP < 100 mmHg)	Cerebrovascular disease	94 (16.6)	14 (21.5)	80 (16.0)	0.25
Peripheral vascular disease85 (15.0)8 (12.3)77 (15.4)0.51Valvulopathy172 (30.4)17 (26.2)155 (31.0)0.42Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI < 45% (n= 175)	Atrial fibrillation	263 (47.1)	26 (40.6)	237 (48.0)	0.26
Valvulopathy172 (30.4)17 (26.2)155 (31.0)0.42Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI ≤ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataHypotension (SBP < 100 mmHg)	Peripheral vascular disease	85 (15.0)	8 (12.3)	77 (15.4)	0.51
Chronic obstructive pulmonary disease126 (22.3)15 (23.1)111 (22.1)0.87Previous episode of heart failure357 (63.2)41 (63.1)316 (63.2)0.98Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI $\leq$ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataHypotension (SBP < 100 mmHg)	Valvulopathy	172 (30.4)	17 (26.2)	155 (31.0)	0.42
Previous episode of heart failure $357 (63.2)$ $41 (63.1)$ $316 (63.2)$ $0.98$ Cirrhosis $17 (3.0)$ $4 (6.2)$ $13 (2.6)$ $0.11$ Cancer $93 (16.5)$ $15 (23.1)$ $78 (15.6)$ $0.12$ Basal situationCardiorespiratory status (NYHA III-IV) $137 (24.6)$ $22 (34.9)$ $115 (23.2)$ $0.04$ LVEFI $\leq 45\% (n = 175)$ $101 (57.7)$ $3 (21.4)$ $71 (44.1)$ $0.10$ Acute episode dataHypotension (SBP < 100 mmHg)	Chronic obstructive pulmonary disease	126 (22.3)	15 (23.1)	111 (22.1)	0.87
Cirrhosis17 (3.0)4 (6.2)13 (2.6)0.11Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situation $Cardiorespiratory status (NYHA III-IV)$ 137 (24.6)22 (34.9)115 (23.2)0.04LVEFI $\leq 45\%$ (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode data $Hypotension (SBP < 100 mmHg)$ 28 (5.0)7 (10.9)21 (4.3)0.02Tachycardia (HR $\geq 100$ bpm)137 (24.6)12 (18.5)125 (25.4)0.22Tachypnea (RR > 20 rpm)222 (39.3)35 (53.8)187 (37.4)0.01Respiratory insufficiency (Basal O <sub>2</sub> Sat < 90%)146 (27.4)29 (45.3)117 (24.9)0.01Hyponatremia (Na < 135 mEq/L)89 (16.0)18 (29.5)71 (14.4)0.01Renal insufficiency (< 60 ml/min/m²)323 (59.0)34 (56.7)289 (59.3)0.69Anemia (Hb < 12 g/L woman andCl < 13 g/l male)305 (54.9)45 (71.4)260 (52.7)0.01Treatment of the acute episode208 (70.6)53 (80.0)287 (57.4)< 0.01	Previous episode of heart failure	357 (63.2)	41 (63.1)	316 (63.2)	0.98
Cancer93 (16.5)15 (23.1)78 (15.6)0.12Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI $\leq 45\%$ (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataHypotension (SBP < 100 mmHg)28 (5.0)7 (10.9)21 (4.3)0.02Tachycardia (HR $\geq 100$ bpm)137 (24.6)12 (18.5)125 (25.4)0.22Tachypnea (RR > 20 rpm)222 (39.3)35 (53.8)187 (37.4)0.01Respiratory insufficiency (Basal O <sub>2</sub> Sat < 90%)146 (27.4)29 (45.3)117 (24.9)0.01Hyponatremia (Na < 135 mEq/L)89 (16.0)18 (29.5)71 (14.4)0.01Renal insufficiency (< 60 ml/min/m²)323 (59.0)34 (56.7)289 (59.3)0.69Anemia (Hb < 12 g/L woman andCl < 13 g/l male)305 (54.9)45 (71.4)260 (52.7)0.01Treatment of the acute episode208 (70.6)53 (80.0)287 (57.4)< 0.01	Cirrhosis	17 (3.0)	4 (6.2)	13 (2.6)	0.11
Basal situationCardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI ≤ 45% (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataHypotension (SBP < 100 mmHg)	Cancer	93 (16.5)	15 (23.1)	78 (15.6)	0.12
Cardiorespiratory status (NYHA III-IV)137 (24.6)22 (34.9)115 (23.2)0.04LVEFI $\leq 45\%$ (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode dataHypotension (SBP < 100 mmHg)	Basal situation				
LVEFI $\leq 45\%$ (n= 175)101 (57.7)3 (21.4)71 (44.1)0.10Acute episode data28 (5.0)7 (10.9)21 (4.3)0.02Hypotension (SBP < 100 mmHg)137 (24.6)12 (18.5)125 (25.4)0.22Tachypnea (RR > 20 rpm)222 (39.3)35 (53.8)187 (37.4)0.01Respiratory insufficiency (Basal O2Sat < 90%)146 (27.4)29 (45.3)117 (24.9)0.01Hyponatremia (Na < 135 mEq/L)89 (16.0)18 (29.5)71 (14.4)0.01Renal insufficiency (< 60 ml/min/m²)323 (59.0)34 (56.7)289 (59.3)0.69Anemia (Hb < 12 g/L woman andCl < 13 g/l male)305 (54.9)45 (71.4)260 (52.7)0.01Treatment of the acute episode208 (20.6)53 (80.0)246 (40.3)246 (40.3)0.07	Cardiorespiratory status (NYHA III-IV)	137 (24.6)	22 (34.9)	115 (23.2)	0.04
Acute episode dataHypotension (SBP < 100 mmHg)	$LVEFI \le 45\%$ (n= 175)	101 (57.7)	3 (21.4)	/1 (44.1)	0.10
Hypotension (SBP < 100 mmHg)28 (5.0)/ (10.9)21 (4.3)0.02Tachycardia (HR $\ge 100$ bpm)137 (24.6)12 (18.5)125 (25.4)0.22Tachypnea (RR > 20 rpm)222 (39.3)35 (53.8)187 (37.4)0.01Respiratory insufficiency (Basal O <sub>2</sub> Sat < 90%)	Acute episode data	00 (F 0)	- (10.0)		
Tachycardia (HR $\geq 100$ bpm)       137 (24.6)       12 (18.5)       125 (25.4)       0.22         Tachypnea (RR $\geq 20$ rpm)       222 (39.3)       35 (53.8)       187 (37.4)       0.01         Respiratory insufficiency (Basal O <sub>2</sub> Sat < 90%)	Hypotension (SBP < 100 mmHg)	28 (5.0)	7 (10.9)	21 (4.3)	0.02
Tachypnea (RR > 20 rpm)222 (39.3)35 (53.8)187 (37.4)0.01Respiratory insufficiency (Basal $O_2Sat < 90\%$ )146 (27.4)29 (45.3)117 (24.9)0.01Hyponatremia (Na < 135 mEq/L)	Tachycardia (HR ≥ 100 bpm)	137 (24.6)	12 (18.5)	125 (25.4)	0.22
Respiratory insufficiency (Basal O <sub>2</sub> Sat < 90%)	Tachypnea (RR > 20 rpm)	222 (39.3)	35 (53.8)	187 (37.4)	0.01
Hyponatremia (Na < 135 mEq/L)	Respiratory insufficiency (Basal O <sub>2</sub> Sat < 90%)	146 (27.4)	29 (45.3)	117 (24.9)	0.01
Renal insufficiency (< 60 ml/min/m²)	Hyponatremia (Na < 135 mEq/L)	89 (16.0)	18 (29.5)	/1 (14.4)	0.01
Anemia (Hb < 12 g/L woman andCl < 13 g/l male)	Renal insufficiency (< 60 ml/min/m <sup>2</sup> )	323 (59.0)	34 (56./)	289 (59.3)	0.69
N1-proBNP > 5,180 pg/ml         339 (60.0)         52 (80.0)         287 (57.4)         < 0.01           Treatment of the acute episode         208 (70.6)         53 (80.0)         246 (70.2)         0.07	Anemia (Hb < 12 g/L woman andCl < 13 g/l male)	305 (54.9)	45 (71.4)	260 (52.7)	0.01
Ireatment of the acute episode	NI-proBNP > 5,180 pg/ml	339 (60.0)	52 (80.0)	287 (57.4)	< 0.01
	Ireatment of the acute episode	200 (70 ()	52 (80.0)	246 (60.2)	0.07
$\begin{array}{cccc} Uxygen & & 576 (70.0) & 52 (50.0) & 546 (57.5) & 0.07 \\ 376 (40) & & 376 (40) & 0.42 \\ 376 (40) & & 376 (40) & 0.4$	Oxygen	396 (70.0)	52 (80.0)	240 (09.5) 20 (4.0)	0.07
Non-invasive ventilation $24(4.3) + (0.2) = 20(4.0) = 0.42$	INON-INVASIVE VENTILATION	24 (4.5) 509 (00 1)	4(0.2)	20 (4.0)	0.42
Intravenous diuretics $300(90.1)$ $02(93.4)$ $440(05.4)$ $0.12$	Intravenous diuretics	20 (5 1)	02 (93.4)	440 (09.4) 25 (5 0)	0.12
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		29 (J.1) 176 (21 2)	4 (0.2)	23 (3.0)	0.09
ACEI ULARA $170(51.2)$ $7(10.0)$ $109(53.2)$ $< 0.01$ Bata blackarr $101(17.0)$ $1(15)$ $100(20.0)$ $< 0.01$	ACEI UI ARA Pata blaskars	101 (17.0)	1 (1 5)	109 (33.9)	< 0.01
Digovin $95(16.8) 9(13.8) 86(17.2) 0.49$	Digoxin	95 (16.8)	9 (13.8)	86 (17.2)	0.49

#### Table 2. Characteristics of patients included according to 30-day mortality

SD: standard deviation; n: number of cases; NYHA: New York Heart Association; SBP: systolic blood pressure; HR: heart rate; RR: respiratory rate; bpm: beats per minute; rpm: breaths per minute; SatO<sub>2</sub>: oxygen saturation; Na: natremia; CI: estimated renal clearance; LVEF: ejection fraction of the left ventricle; Hb: hemoglobin; ACE inhibitors: angiotensin converting enzyme inhibitors; ARA: angiotensin receptor antagonist.

HES and that the presence of acute confusional syndrome, of frailty or severe functional dependence, and of the subjective state of health and nutrition in the last 3 months, are factors that could be associated independently with the 30-day global mortality. These findings indicate that the described geriatric variables should be considered in the future in the design of risk prediction models in patients aged 65 or older treated for AHF.

Our results are in line with previous studies on the high frequency of comorbidity, polypharmacy and geriatric syndromes in the elderly with AHF and its progressive increase as age advances<sup>21,22</sup>. More than half of the elderly with AHF presented altered activities of daily living and one in ten suffered severe disability. Fragility was present in one in four elderly people without serious dependence. Acute confusional syndrome occurred in one in ten cases. These data are in the range of previous studies and the possible differences found can be explained by the different measurement tools and fields of study<sup>13,17,19,23-25</sup>. The relevant aspect of this study is that it was carried out in a cohort of patients aged 65 years and older treated by AHF in Spanish HES, and that it did not exclude, in comparison with other registries, the elderly discharged directly from the HES<sup>1</sup>.

The data shown provide evidence of the 30-day prognostic value of cognitive, physical and nutritional fragility in elderly patients treated with AHF in HES. Previous studies have shown that frailty and severe disability are predictors of short-term mortality<sup>8,26</sup>, and long-term<sup>17</sup>, and that acute confusional syndrome is associated with poor intrahospital prognosis<sup>13,25</sup> and short-term after discharge<sup>13,24,25</sup> and that malnutrition has a long-term prognostic effect<sup>27</sup>. An important aspect to consider is that these geriatric variables can be potentially reversible if an adequate pharmacological and non-pharmacological treatment is established<sup>28-30</sup>. In this sense, we would like to emphasize the importance of identifying these geriatric variables in the systematic assessment of el-

Table 3. Ur	nivariate analy	/sis of the ger	atric variable	s associated w	ith mortality	/ 30 da	iys
-------------	-----------------	-----------------	----------------	----------------	---------------	---------	-----

Variable	Frequency n (%)	Mortality 30 days (%)	р
Acute illness in the last 3 months Yes No	120/565 (21.2)	25 (20.8) 40 (9.0)	< 0.01
Severe Comorbidity (Charlson Index ≥ 3) Yes No	329/565 (58.2)	44 (13.4) 21 (8.9)	0.1
Polymedicated (number of drugs ≥ 5) Yes No	512/565 (90.6)	60 (11.7) 5 (9.4)	0.62
Acute confusional syndrome (positive CAM) Yes No	55/565 (9.7)	19 (34.5) 46 (9.0)	< 0.01
History of dementia Yes No	102/565 (18.1)	26 (25.5) 39 (8.4)	< 0.01
Positive dementia screening (SIS ≥ 3) Yes No	153/510 (30.0)	16 (10.5) 30 (8.4)	0.45
History of depression Yes No	152/565 (26.9)	25 (16.4) 40 (9.7)	0.02
Positive Depression Screening (GDS-5 ≥ 2) Yes No	156/510 (30.6)	14 (9.0) 32 (9.0)	0.98
Visual acuity deficit Yes No	272/565 (48.2)	39 (14.3) 25 (8.6)	0.03
Hearing acuity deficit Yes No	225/565 (40.3)	31 (13.8) 32 (9.6)	0.12
Loss of appetite in the last 3 months Yes No	154/565 (27.3)	32 (20.8) 33 (8.0)	< 0.01
Fragility-disability Non-frail or severe functional dependence Fragile without serious functional dependence ( $\geq$ 3 weakened criteria BI $\geq$ 40) Serious functional dependence (IB < 40)	304/565 (53.8) 201/565 (35.6) 60/565 (10.6)	15 (4.9) 28 (13.9) 22 (36.7)	< 0.01
Lives alone Yes No	47/565 (8.4)	3 (6.4) 62 (12.1)	0.24

CAM: Confussion Assessment Method; SIS: Six-Item Screener; GDS: Geriatric Depression Scale; BI: Barthel Index.

derly patients with AHF during their urgent attention in order to improve risk stratification and establish a specific care plan in order to reverse these situations.

The present study has several limitations. It is an exploratory study from a multipurpose registry, and therefore the statistical power of the analysis may have been limited. Although no clinically relevant differences were found between the group of patients included and not included, it cannot be ruled out that this fact could have influenced the mortality rates or a selection bias, since a systematic sampling was carried out where the adapted geriatric assessment the emergency department was performed from 8 am to 10 pm on working days. Information on echocardiographic data, such as left ventricle function, and prognostic biomarkers, such as troponin, were not available in some patients, since they are not performed routinely in all patients treated for AHF in Spanish HES. The treatments prescribed during the acute phase and after discharge from the

patient were at the discretion of the physicians responsible for care, and therefore this could have had an influence on the results. However, this allows the results to be more real and finally can be more easily applied to clinical practice.

It is concluded that the inclusion of activities of daily living (Barthel index) and the physical fragility (fragility phenotype questionnaire) and nutritional fragility (two subjective questions about health or nutrition in the last 3 months) are key variables when stratifying the risk at 30 days among the elderly served by AHF in the HES.

# **Conflicting interests**

The authors declare no conflict of interest in relation to this article.

#### Financing

The authors declare the non-existence of external financing of this article.



**Figure 1.** Crude and adjusted effects of the non-geriatric variables with respect to 30-day mortality in the elderly with acute heart failure. Adjusted 1: acute illness in the last 3 months, severe comorbidity, polymedicated, acute confusional syndrome, history of dementia and depression, deficit of visual and auditory acuity, weight loss in the last 3 months, fragility and grouped disability, and living alone. Adjusted 2: adjusted for acute illness in the last 3 months, severe comorbidity, polymedicated, acute confusional syndrome, history of dementia and depression, deficit of visual and auditory acuity, weight loss in the last 3 months, fragility and grouped disability, live alone, age  $\geq$  75 years old, female sex, history of diabetes mellitus, cerebrovascular disease, cancer, episode of previous heart failure, baseline cardiorespiratory NYHA III-IV, systolic blood pressure < 100 mmHg, baseline oxygen saturation < 90%, respiratory rate > 20 rpm, renal clearance < 60 ml/min, hemoglobin < 12 g/L women and < 13 g/l men, natremia < 135 mEq/l, and NT-proBNP > 5,180 pg/ml.

#### **Ethical Responsibilities**

The Clinical Research Ethics Committees of the hospitals participating in the study (Hospital Clínico San Carlos in Madrid, Hospital Reina Sofía in Murcia and Hospital de la Santa Creu i Sant Pau in Barcelona) approved the realization of the same. All patients gave their informed consent to participate in the study. All authors have confirmed the maintenance of confidentiality and respect for the rights of patients in the author's responsibility document, publication agreement and assignment of rights to EMERGENCIAS.

# Article not commissioned by the Editorial Committee and with external peer review

# **Acknowledgements**

The present study was made possible in part thanks to the PI15/00773, PI15/ 01019, PI11/01021 and PI10/01918 grants from the Instituto de Salud Carlos III from funds of the Ministry of Health, Social Services and Equality (MSSSI) and the Fund European Regional Development (FEDER); to the grants of the Generalitat de Catalunya for Consolidated Research Groups (GRC 2009/1385 and 2014/0313); and the La Marató TV3 scholarship (2015/2510).

# Addendum

List of OAK Registry researchers: María José Pérez-Durá, Pablo Berrocal Gil (La Fe Hospital of Valencia). Óscar Miró, Víctor Gil Espinosa, Carolina Sánchez, Sira Aquiló (Hospital Clínic de Barcelona). Maria Àngels Pedragosa Vall, Alfons Aguirre (Hospital del Mar de Barcelona). Pascual Piñera, Paula Lázaro Aragues, José Andrés Sánchez Nicolás (Queen Sofia Hospital of Murcia). Miguel Alberto Rizzi Bordigoni, Aitor Alguézar, Sergio Herrera Mateo (Hospital San Pau de Barcelona). Fernando Richard (Hospital of Burgos). Javier Jacob, Carles Ferrer, Ferrán Llopis (Hospital Universitari de Bellvitge, Barcelona). F. Javier Martín Sánchez, Juan González del Castillo, Esther Rodríguez-Adrada, Guillermo Llopis García, Eduardo Anguita Mandly, Julián Sanz Ortega, María de los Ángeles Cuadrado Cenzual, María Dolores Inés Ortega of Heredia, Cristina Fernández Pérez (Hospital Clínico San Carlos, Madrid). Pere Llorens Soriano, José María Fernández-Cañadas, José Manuel Carratalá, Patricia Javaloyes (General University Hospital of Alicante). Pablo Herrero Puente, Iván Rancaño García, María Fernández Coya (Central University Hospital of Asturias). José Antonio Sevillano Fernández, Juan Andueza (University Hospital Gregorio Marañón of Madrid). Rodofo Romero Pareja (University Hospital of Getafe, Madrid). Carmen del Arco (University Hospital of La Princesa de Madrid). Alfonso Martín, Raquel Torres (University Hospital Severo Ochoa de Leganés, Madrid). Belén Rodríguez Miranda (University Hospital Rey Juan Carlos de Móstoles, Madrid). Carlos Bibiano Guillén (Infanta Leonor de Vallecas University Hospital, Madrid).

# References

- 1 Llorens P, Escoda R, Miró O, Herrero Puente P, Martín-Sánchez FJ, Jacob J, et al. Characteristics and clinical course of patients with acute heart failure and the therapeutic measures applied in Spanish emergency departments: based on the EAHFE registry (Epidemiology of Acute Heart Failure in Emergency Departments). Emergencias. 2015;27:11-22.
- 2 Miró O, Llorens P, Escalada X, Herrero P, Jacob J, Gil V, et al. Atención prehospitalaria a los pacientes con insuficiencia cardiaca aguda en España: estudio SEMICA. Emergencias. 2017;29:223-30.
- 3 Harjola P, Harjola VP. ¿Podemos hacer más por los pacientes con insuficiencia cardiaca aguda en la fase prehospitalaria?. Emergencias. 2017;29:221-2.
- 4 Miró Ò, Levy PD, Möckel M, Pang PS, Lambrinou E, Bueno H, et al. Disposition of emergency department patients diagnosed with acute heart failure: an international emergency medicine perspective. Eur J Emerg Med. 2017;24:2-12.
- 5 Carbajosa V, Martín-Sánchez FJ, Llorens P, Herrero P, Jacob J, Alquézar A, et al. Factores asociados a estancias cortas en los pacientes ingresados por insuficiencia cardiaca aguda. Emergencias. 2016;28:366-74.
- 6 Peacock WF. ¿Cuándo y durante cuánto tiempo tienen que estar ingresados los pacientes con insuficiencia cardiaca aguda?. Emergencias. 2016;28:363-5.
- 7 Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-7. 8 Martín-Sánchez FJ, Gil V, Llorens P, Herrero P, Jacob J, Fernández C, et
- al. Barthel Index-Enhanced Feedback for Effective Cardiac Treatment (BI-EFFECT) Study: contribution of the Barthel Index to the Heart Failure Risk Scoring System model in elderly adults with acute heart failure in the emergency department. J Am Geriatr Soc. 2012;60:493-8. 9 Stiell IG, Clement CM, Brison RJ, Rowe BH, Borgundvaag B, Aaron

SD, et al. A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events. Acad Emerg Med. 2013:20:17-26.

- 10 Collins SP, Jenkins CA, Harrell FE Jr, Liu D, Miller KF, Lindsell CJ, et al. Identification of Emergency Department Patients With Acute Heart Failure at Low Risk for 30-Day Adverse Events: The STRATIFY Decision Tool. JACC Heart Fail. 2015;3:737-47.
- 11 Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail. 2014:2:429-36.
- 12 Ruiz-Laiglesia FJ, Sánchez-Marteles M, Pérez-Calvo JI, Formiga F, Bartolomé-Satué JA, Armengou-Arxé A, et al. Comorbidity in heart failu-re. Results of the Spanish RICA Registry. QJM. 2014;107:989-94. 13 Uthamalingam S, Gurm GS, Daley M, Flynn J, Capodilupo R. Useful-
- ness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure. Am J Cardiol. 2011;108:402-8.
- 14 Formiga F, Chivite D, Solé A, Manito N, Ramon JM, Pujol R. Functional outcomes of elderly patients after the first hospital admission for decompensated heart failure (HF). A prospective study. Arch Gerontol Geriatr. 2006;43:175-85.
- 15 Luttik ML, Jaarsma T, Moser D, Sanderman R, van Veldhuisen DJ. The importance and impact of social support on outcomes in patients with heart failure: an overview of the literature. | Cardiovasc Nurs. 2005;20:162-9.
- 16 Argues S, Roux E, Stolidi P, Gelisse R, Ambrosi P. Usefulness of serum albumin and serum total cholesterol in the prediction of hospital death in older patients with severe, acute heart failure. Arch Cardiovasc Dis. 2011;104:502-8.
- 17 Vidán MT, Blaya-Novakova V, Sánchez E, Ortiz J, Serra-Rexach JA, Bueno H. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail. 2016:18:869-75.
- 18 Sánchez E, Vidán MT, Serra JA, Fernández-Avilés F, Bueno H. Prevalence of geriatric syndromes and impact on clinical and functional outcomes in older patients with acute cardiac diseases. Heart. 2011;97:1602-6.
- 19 Martín-Sánchez FJ, Rodríguez-Adrada E, Mueller C, Vidán MT, Christ M, Peacock WF, et al. The effect of frailty on 30-day mortality risk in older patients with acute heart failure attended in the Emergency Department. Acad Emerg Med. 2016;24:298-307. 20 Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
- Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008:10:933-89
- 21 Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polyphar-macy and treatment dilemmas. Eur J Heart Fail. 2002;4:91-8.
- 22 Martín-Sánchez FJ, Marino-Genicio R, Rodríguez-Adrada E, Jacob J, Herrero P, Miró O, et al. Management of acute heart failure in spanish emergency departments based on age. Rev Esp Cardiol. 2013;66:715-20.
- 23 Dunlay SM, Manemann SM, Chamberlain AM, Cheville AL, Jiang R, Weston SA, et al. Activities of daily living and outcomes in heart failure. Circ Heart Fail. 2015;8:261-7
- 24 Rizzi MA, Torres Bonafonte OH, Alquezar A, Herrera Mateo S, Piñera P, et al. Prognostic value and risk factors of delirium in emergency patients with decompensated heart failure. J Am Med Dir Assoc. 2015;16:799.
- 25 Honda S, Nagai T, Sugano Y, Okada A, Asaumi Y, Aiba T, et al. Prevalence, determinants, and prognostic significance of delirium in patients with acute heart failure. Int J Cardiol. 2016;222:521-7
- 26 Miró O, Llorens P, Martín-Sánchez FJ, Herrero P, Pavón J, Pérez-Durá MJ, et al. Short-term prognostic factors in elderly patients seen in emergency departments for acute heart failure. Rev Esp Cardiol. 2009;62:757-64
- 27 Lin H, Zhang H, Lin Z, Li X, Kong X, Sun G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. Heart Fail Rev. 2016;21:549-65.
- 28 Ng TP, Feng L, Nyunt MS, Feng L, Niti M, Tan BY, et al. Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial. Am J Med. 2015;128:1225-36.
- 29 Inouye SK. Delirium in older persons. N Engl J Med. 2006;354:1157-65.
- 30 Deutz NE, Matheson EM, Matarese LE, Luo M, Baggs GE, Nelson JL, et al. Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: A randomized clinical trial. Clin Nutr. 2016;35:18-26.